Genes or environment to determine alcoholic liver disease and non‐alcoholic fatty liver disease

Abstract: While the vast majority of heavy drinkers and individuals with obesity, insulin resistance, and the metabolic syndrome will have steatosis, only a minority will ever develop steatohepatitis, fibrosis, and cirrhosis. Genetic and environmental risk factors for advanced alcoholic liver disease (ALD) and non‐alcoholic fatty liver disease (NAFLD) seem likely to include factors that influence the severity of steatosis and oxidative stress, the cytokine milieu, the magnitude of the immune response, and/or the severity of fibrosis. For ALD, the dose and pattern of alcohol intake, along with obesity are the most important environmental factors determining disease risk. For NAFLD, dietary saturated fat and antioxidant intake and small bowel bacterial overgrowth may play a role. Family studies and interethnic variations in susceptibility suggest that genetic factors are important in determining disease risk. For ALD, functional polymorphisms in the alcohol dehydrogenases and aldehyde dehydrogenase alcohol metabolising genes play a role in determining susceptibility in Oriental populations. No genetic associations with advanced NAFLD have been replicated in large studies. Preliminary data suggest that polymorphisms in the genes encoding microsomal triglyceride transfer protein, superoxide dismutase 2, the CD14 endotoxin receptor, TNF‐α, transforming growth factor‐β, and angiotensinogen may be associated with steatohepatitis and/or fibrosis.

[1]  R. González-Sarmiento,et al.  -238 G>A polymorphism of tumor necrosis factor alpha gene (TNFA) is associated with alcoholic liver cirrhosis in alcoholic Spanish men. , 2005, Alcoholism, clinical and experimental research.

[2]  J. Grove,et al.  The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. , 1998, Pharmacogenetics.

[3]  D. Pessayre,et al.  Homozygosity for alanine in the mitochondrial targeting sequence of superoxide dismutase and risk for severe alcoholic liver disease. , 2001, Gastroenterology.

[4]  S. Uchida,et al.  Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase , 2002, Nature Medicine.

[5]  A. Lonardo,et al.  Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.

[6]  G. Omenn,et al.  Evidence of genetic predisposition to alcoholic cirrhosis and psychosis: twin concordances for alcoholism and its biological end points by zygosity among male veterans. , 1981, Alcoholism, clinical and experimental research.

[7]  I. Roberts-Thomson,et al.  The role of small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia, and tumour necrosis factor α in the pathogenesis of non-alcoholic steatohepatitis , 2001, Gut.

[8]  F. Chang,et al.  Chinese alcoholic patients with esophageal cancer are genetically different from alcoholics with acute pancreatitis and liver cirrhosis , 2000, American Journal of Gastroenterology.

[9]  David E. J. Jones,et al.  Oxidative stress as a trigger for cellular immune responses in patients with alcoholic liver disease , 2004, Hepatology.

[10]  I. Leclercq,et al.  Central role of PPARα‐dependent hepatic lipid turnover in dietary steatohepatitis in mice , 2003, Hepatology.

[11]  O. Yokosuka,et al.  High incidence of ADH2*1/ALDH2*1 genes among Japanese alcohol dependents and patients with alcoholic liver disease , 1996, Hepatology.

[12]  B. Grant,et al.  The critical dimension of ethnicity in liver cirrhosis mortality statistics. , 2001, Alcoholism, clinical and experimental research.

[13]  P. Bedossa,et al.  Risk factors of fibrosis in alcohol‐induced liver disease , 2002, Hepatology.

[14]  Mauro Santos,et al.  Genetic polymorphism of alcohol dehydrogenase in europeans: TheADH2*2 allele decreases the risk for alcoholism and is associated with ADH3*1 , 2000, Hepatology.

[15]  J. Peters,et al.  The human peroxisome proliferator-activated receptor alpha gene: identification and functional characterization of two natural allelic variants. , 2000, Pharmacogenetics.

[16]  David C. Jones,et al.  Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease , 2003, Hepatology.

[17]  G. Musso,et al.  Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis , 2003, Hepatology.

[18]  J. Grove,et al.  Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease , 2000, Gut.

[19]  C. Clark,et al.  Trends in alcohol-related problems among whites, blacks, and Hispanics: 1984-1995. , 1998, Alcoholism, clinical and experimental research.

[20]  S. Horwitz,et al.  Mechanism of action of taxol. , 1992, Trends in pharmacological sciences.

[21]  L. N. Valenti,et al.  Tumor necrosis factor α promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease , 2002 .

[22]  S. Caldwell,et al.  Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. , 2000, The American journal of medicine.

[23]  J. Durbec,et al.  Diet and alcohol in liver cirrhosis: a case-control study. , 1990, European journal of clinical nutrition.

[24]  C. Day From fat to inflammation. , 2006, Gastroenterology.

[25]  I. Wanless,et al.  Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors , 1990, Hepatology.

[26]  A. Gasbarrini,et al.  Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test , 2003, American Journal of Gastroenterology.

[27]  A. Andriulli,et al.  Efficacy of 5 MU of interferon in combination with ribavirin for naïve patients with chronic hepatitis C virus: a randomized controlled trial. , 2001, Journal of hepatology.

[28]  C. Fan,et al.  Steatohepatitis, Spontaneous Peroxisome Proliferation and Liver Tumors in Mice Lacking Peroxisomal Fatty Acyl-CoA Oxidase , 1998, The Journal of Biological Chemistry.

[29]  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease , 2001 .

[30]  Rahul Krishnarao Patil,et al.  Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease , 2001, American Journal of Gastroenterology.

[31]  G. Marchesini,et al.  Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver , 2004, Hepatology.

[32]  T. Mak,et al.  CTLA‐4, a Negative Regulator of T‐Lymphocyte Activation , 1996, Immunological reviews.

[33]  C. Day,et al.  Manganese dependent superoxide dismutase (SOD2) targeting sequence polymorphism is associated with advanced fibrosis in patients with non-alcoholic fatty liver disease , 2003 .

[34]  J. Grove,et al.  Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis , 1997, Hepatology.

[35]  C. Day,et al.  Alcoholic liver disease: new insights into mechanisms and preventative strategies. , 2001, Trends in molecular medicine.

[36]  J. Dixon,et al.  Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. , 2001, Gastroenterology.

[37]  J. Kench,et al.  Beyond insulin resistance in NASH: TNF‐α or adiponectin? , 2004, Hepatology.

[38]  Y. Chao,et al.  Alcoholism and alcoholic organ damage and genetic polymorphisms of alcohol metabolizing enzymes in Chinese patients , 1997, Hepatology.

[39]  J. Patrie,et al.  Is NASH underdiagnosed among African Americans? , 2002, American Journal of Gastroenterology.

[40]  C. Day,et al.  Hepatic steatosis: Innocent bystander or guilty party? , 1998, Hepatology.

[41]  S. Aricó,et al.  Cytotoxic T-lymphocyte antigen-4 A49G polymorphism is associated with susceptibility to and severity of alcoholic liver disease in Italian patients. , 2004, Alcohol and alcoholism.

[42]  K K Kidd,et al.  Linkage disequilibrium at the ADH2 and ADH3 loci and risk of alcoholism. , 1999, American journal of human genetics.

[43]  M. Vidali,et al.  Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. , 2002, Hepatology.

[44]  Luc J. Smink,et al.  Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease , 2003, Nature.

[45]  M. Perola,et al.  Promoter polymorphism of the CD14 endotoxin receptor gene as a risk factor for alcoholic liver disease , 2001, Hepatology.

[46]  M. Saboorian,et al.  Ethnic Differences in the Prevalence of Cryptogenic Cirrhosis , 2004, American Journal of Gastroenterology.

[47]  J. Grove,et al.  Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease , 1998, Gut.

[48]  D. Brenner,et al.  Estriol sensitizes rat Kupffer cells via gut-derived endotoxin. , 1999, American journal of physiology. Gastrointestinal and liver physiology.

[49]  G. Brandi,et al.  Drinking habits as cofactors of risk for alcohol induced liver damage , 1997, Gut.

[50]  C. Day Pathogenesis of steatohepatitis. , 2002, Best practice & research. Clinical gastroenterology.

[51]  D. Schwartz,et al.  TLR4 mutations are associated with endotoxin hyporesponsiveness in humans , 2000, Nature Genetics.

[52]  J. Dixon,et al.  Pro-fibrotic polymorphisms predictive of advanced liver fibrosis in the severely obese. , 2003, Journal of hepatology.

[53]  F. Capron,et al.  Excess weight risk factor for alcoholic liver disease , 1997, Hepatology.

[54]  P. Moulin,et al.  Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with Type II diabetes , 2000, Diabetologia.

[55]  C. Day,et al.  Candidate gene case-control association studies: advantages and potential pitfalls. , 2001, British journal of clinical pharmacology.

[56]  J. Berger,et al.  The mechanisms of action of PPARs. , 2002, Annual review of medicine.

[57]  C. Day CD14 promoter polymorphism associated with risk of NASH , 2002 .

[58]  P. Ward,et al.  Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. , 1998, Gastroenterology.

[59]  H. Shimano,et al.  Polyunsaturated fatty acids ameliorate hepatic steatosis in obese mice by SREBP‐1 suppression , 2003, Hepatology.

[60]  P. Holt,et al.  A Polymorphism* in the 5' flanking region of the CD14 gene is associated with circulating soluble CD14 levels and with total serum immunoglobulin E. , 1999, American journal of respiratory cell and molecular biology.

[61]  Yu Wang,et al.  The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. , 2003, The Journal of clinical investigation.

[62]  J. Patrie,et al.  Is NASH underdiagnosed among African Americans , 2002 .

[63]  T. Sørensen,et al.  Lower risk for alcohol‐induced cirrhosis in wine drinkers , 2002, Hepatology.

[64]  J. Clore,et al.  Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. , 2001, Gastroenterology.